

- 14 -

Amendment A
U.S. Application Serial No. 09/783,969
Group Art Unit 1614

EXHIBIT B

CLEAN SET OF ALL PENDING CLAIMS
FOLLOWING ENTRY OF THE PRESENT AMENDMENT

R¹ Sub C1
1. A pharmaceutical composition comprising an emulsion preconcentrate including a cyclosporin dissolved in a solvent system comprising substantially fully acetylated monoglycerides having a minimum acetylation of 96%, a hydrophilic organic solvent and at least two surfactants.

Sub C2
15. A pharmaceutical composition comprising a micro emulsion preconcentrate having a droplet size of substantially less than 2000 Å, including a cyclosporin dissolved in an acetylated monoglyceride lipophilic solvent, and a surfactant.

16. The composition of claim 1 in the form of a microemulsion preconcentrate.

R2
17. The composition of claim 15 wherein the acetylated monoglyceride is a fully acetylated monoglyceride prepared from unsaturated monoglyceride.

18. The composition of claim 1 or 15 wherein the surfactant is selected from the group of a polyoxyethylene glycolated natural, hydrogenated vegetable oil, polyoxyl 40 hydrogenated castor oil, and a polyoxyethylene-sorbitan-fatty ester.

19. The composition of claim 1 or 15 comprising two surfactants, one of which is a polyoxyethylene glycolated natural or hydrogenated vegetable oil and the second of which is a polyoxyethylene-sorbitan-fatty acid ester.

- 15 -

20. The composition of claim 15 further comprising a hydrophilic organic solvent miscible with the acetylated monoglyceride lipophilic solvent.

21. The composition of claim 20 wherein said hydrophilic organic solvent is selected from the group of ethanol, propylene glycol, propylene carbonate, benzyl alcohol, and polyethylene glycol having mean molecular weight of less than about

1000.

add
C3